XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide ...Middle East

Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Results show the potential for XTANDI to add to the standard of care in prostate cancer, if approved TOKYO and NEW YORK, April 29, 2023 /PRNewswire/ --...

Hence then, the article about xtandi enzalutamide plus leuprolide reduced the risk of metastasis by 58 in non metastatic hormone sensitive prostate cancer versus placebo plus leuprolide was published today ( Saturday 29/04/2023 - 06:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide )

Also on site :

• My Wife Doesn’t Know I Watched Her Cheat On Me. My Reaction Might Shock Us Both.
• The Good Ship Murder Christmas special cast: Meet the characters
• Eight fire crews tackling blaze at West Midlands Wetherspoon pub